In ER-positive BC cells that have developed endocrine resistance, ER expression may be suppressed directly by enhanced peptide growth factor receptor signaling that is due to overexpression of the type I growth factor receptors, such as EGFR and HER2, with subsequent downstream MAPK activation that inhibits ER transcriptional expression 29. This evidence concerns the gene ERBB2 and breast cancer.